How many drugs treat Polymyalgia rheumatica?

Drug Landscape tracks 3 marketed treatments for Polymyalgia rheumatica (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/polymyalgia-rheumatica.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Polymyalgia rheumatica — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Polymyalgia rheumatica (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Polymyalgia rheumatica, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Intra-articular corticosteroid injections	intra-articular-corticosteroid-injections	Pfizer	Corticosteroid	Glucocorticoid receptor
prednisolon	prednisolon	Hannover Medical School		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (originally Schering) · 1 drug in Polymyalgia rheumatica
Hannover Medical School · 1 drug in Polymyalgia rheumatica
Pfizer · 1 drug in Polymyalgia rheumatica

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Polymyalgia rheumatica:

Cite this brief

Drug Landscape (2026). Polymyalgia rheumatica — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/polymyalgia-rheumatica. Accessed 2026-06-10.

Polymyalgia rheumatica full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing